 |
|
Combining math and medicine to treat leukemia
June 20, 2008Researchers have produced a mathematical model that may lead to the development of an optimally-timed vaccine for chronic myelogenous leukemia (CML). The model takes into account the natural anti-leukemia response in patients that are treated with the drug imatinib. This approach provides insights on how to improve the treatment of leukemia patients. Details are published June 20th in the open-access journal PLoS Computational Biology.
The study represents a collaboration between researchers at the University of Maryland, Stanford University, and École Supérieure d'Électricité (Gif-sur-Yvette, France).
"By combining novel biological data and mathematical modeling, we found rules for designing adaptive treatments for each specific patient," said Professor Doron Levy. "Give me a thousand patients and, with this mathematical model, I can give you a thousand different customized treatment plans."
The study by Levy, Professor Peter P. Lee and Dr. Peter S. Kim uses data collected over four years from CML patients during imatinib therapy.
"Our results suggest that it is not only the drug that sends the leukemia into remission, it's also the natural immune response," Levy said. "After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak [as the leukemia cells are greatly diminished in number]. This typically happens well into the treatment."
This provides a window for cancer cells to develop drug resistance that could render the therapy ineffective. The authors therefore recommend strengthening the immune system at this, its weakest point through "cancer vaccines" in which pre-therapy blood taken from patients is irradiated to kill active cancer cells and then introduced back to the patient.
Levy and Lee are currently conducting further studies to expand on the results of this research, which they hope will lead to the development of animal models and, eventually, clinical trials.
Public Library of Science
The study by Levy, Professor Peter P. Lee and Dr. Peter S. Kim uses data collected over four years from CML patients during imatinib therapy.
"Our results suggest that it is not only the drug that sends the leukemia into remission, it's also the natural immune response," Levy said. "After starting imatinib, the anti-leukemia immune response gradually increases. However, it begins to weaken after it reaches a peak [as the leukemia cells are greatly diminished in number]. This typically happens well into the treatment."
This provides a window for cancer cells to develop drug resistance that could render the therapy ineffective. The authors therefore recommend strengthening the immune system at this, its weakest point through "cancer vaccines" in which pre-therapy blood taken from patients is irradiated to kill active cancer cells and then introduced back to the patient.
Levy and Lee are currently conducting further studies to expand on the results of this research, which they hope will lead to the development of animal models and, eventually, clinical trials.
Public Library of Science
Leukemia Current Events and Leukemia News RSSHodgkin lymphoma -- new characteristics discovered
Researchers are still discovering new characteristics of Hodgkin lymphoma, a common form of cancer of the lymphatic system. The malignant cells are derived from white blood cells (B cells), but have lost a considerable part of the B cell-specific gene expression pattern.
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
New research to help dogs with cancer may benefit people
A new study jointly conducted by Oregon State University College of Veterinary Medicine and the Oregon Health & Science University Cancer Institute may one day help not only our canine friends with cancer, but also people with the human form of the disease.
Embryonic stem cells might help reduce transplantation rejection
Researchers have shown that immune-defense cells influenced by embryonic stem cell-derived cells can help prevent the rejection of hearts transplanted into mice, all without the use of immunosuppressive drugs.
VCU Massey Cancer Center Spearheads Novel Clinical Study for Lymphoma Patients
The Virginia Commonwealth University Massey Cancer Center recently opened a National Cancer Institute (NCI)-sponsored, phase II clinical study for certain sub-types of non-Hodgkin's lymphoma.
New insights into the regulation of PTEN tumor suppression function
The PTEN tumor suppressor gene controls numerous biological processes including cell proliferation, cell growth and death. But PTEN is frequently lost or mutated; in fact, alteration of the gene is so common among various types of human cancer that PTEN has become one of the most frequently mutated of all tumor suppressors.
Children's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Newly discovered molecular switch helps decide cell type in early embryo development
Researchers have discovered a central molecular switch in fruit fly embryos that opens new avenues for studying the causes of birth defects and cancer in humans. Writing about their study in the Aug. 12 Developmental Cell, scientists at Cincinnati Children's Hospital Medical Center determined the switch to be a main tuning mechanism for instructing cells whether to form sensory nerves or blood cells in different parts of the body.
McGill researchers overcome chemotherapy resistance in the lab
Researchers from McGill University's Faculty of Medicine have discovered a compound that reduces resistance to chemotherapy agents used to treat cancer. Their results were published in the June issue of The Journal of Clinical Investigation (JCI).
Crucial Factors in Lymphoma Development and Survival Discovered
Researchers at National Jewish Medical and Research Center have discovered an important factor in the development of B-cell lymphomas, one of the fastest growing forms of cancer.
More Leukemia Current Events and Leukemia News Articles
 | Childhood Leukemia: A Guide for Families, Friends and Caregivers (3rd Edition) by Nancy Keene This most complete parent guide covers not only detailed and precise medical information about leukemia and the various treatment options, but also day-to-day practical advice on how to cope with procedures, hospitalization, family and friends, school, social and financial issues, communication, feelings, and, if therapy is not successful, the difficult issues of death and bereavement. Woven... |
 | 100 Q&A About Leukemia, Second Edition (100 Questions & Answers about . . .) by Edward D. Ball This book deals with leukemia from a doctor's and a patient's... |
 | Adult Leukemia: A Comprehensive Guide for Patients and Families Tens of thousands of Americans are living with adult leukemia, a cancer of the white blood cells. Adult leukemia, which is really a group of diseases, can be a baffling condition for patients and families to understand, and finding targeted information on individual conditions can be difficult. In straightforward, non-technical language, Adult Leukemia: A Comprehensive Guide for Patients and... |
 | Dx/rx: Leukemia (Jones and Bartlett Publishers Dx/Rx Oncology Series) by John Burke Tightly organized into a super-condensed outline bulleted format, this handy, pocket-sized manual details precise, up-to-date information for diagnosis and treatment of Leukemia. Throughout the book, tables and figures summarize important clinical data and current professional society recommendations, while salient references direct readers to additional information. Current, quick, and concise,... |
 | You and Leukemia: A Day at a Time by Lynn S. Baker When a child is diagnosed with leukemia, this is the book for the child and family to read. Known as 'the red book' in the leukemia community, You and Leukemia is written for children, but is often used by adults with leukemia, as well. The new second edition continues to make a challenging disease easier to understand for both children and adults. Extensively illustrated and written in a... |
 | The Cure of Childhood Leukemia: Into the Age of Miracles by John Laszlo |
 | The Official Patient's Sourcebook on Chronic Lymphocytic Leukemia: A Revised and Updated Directory for the Internet Age by Icon Health Publications This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to chronic lymphocytic leukemia (also Chronic granulocytic leukemia; chronic... |
 | Understanding Leukemias, Lymphomas and Myelomas by Tariq Mughal, John M. Goldman, Sabena Mughal A practical, easy-to-use guide to leukemias and lymphomas, Understanding Leukemia and Lymphoma is an invaluable text for everyone involved with these conditions, from specialists in training to interested patients. Using straightforward terminology and extensive color figures to describe and illustrate the current procedures involved in diagnosis and treatment, this is a ready source of up to... |
 | Living Through Leukemia: A Journey to Health by Louis George Whitehead While many believe that being diagnosed with leukemia is like being handed a death sentence, South Dakota native Louis George Whitehead provides living proof that survival of this life-threatening and life-changing illness is possible. At age twenty-one, Whitehead’s doctor informs him that he is suffering from acute myeloid leukemia. After two rounds of chemotherapy and a relapse a few months... |
 | Everything You Need to Know About When Someone You Know Has Leukemia (Need to Know Library) by Heather Moehn |
| © 2008 BrightSurf.com |